Critical Care Anxiety and Long-Term Outcomes Management (CALM)

October 28, 2016 updated by: Jennifer Jutte, University of Washington
The aims of this study are to (1) test the benefits of a non-pharmacologic anxiety management approach with patients who are critically ill and/or traumatically injured during intensive care hospitalization and (2) test whether this approach reduces anxiety and improves engagement in rehabilitation therapies, shortens duration of hospitalization, and improves psychological and quality of life outcomes.

Study Overview

Status

Terminated

Conditions

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Phase 2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years or older
  • Ability to read, write, and speak English
  • Alert (Best RASS ICU sedation score ≥-2)
  • Current CAM-ICU test negative
  • Expected ICU stay ≥48 hours
  • Anxiety Visual Analog Scale (VAS-A) score ≥30
  • Prescribed rehabilitation therapy at eligibility

Exclusion Criteria:

  • Inability to communicate (verbally, or via hand writing/gestures)
  • Greater than 90% probability of mortality in hospital
  • Anticipated discharge to hospice or transition to end-of-life care
  • Pre-existing cognitive impairment (e.g., dementia, pervasive developmental disorder)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anxiety Management (AM)
The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and "optional" modules based on each participant's anxiety experience and preference.
Placebo Comparator: Usual Care (UC)
The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety (Visual Analog Scale for Anxiety (VAS-A)
Time Frame: Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 days
Anxiety at discharge and change in anxiety from baseline to discharge as measured by the Visual Analog Scale for Anxiety (VAS-A)
Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)
Time Frame: As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days)
As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days)
Length of ICU and Hospital Stay
Time Frame: Measured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days)
Measured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days)
Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: 3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS)
3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS)
Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)
Time Frame: 3 months after enrollment as measured by the PCL-5
3 months after enrollment as measured by the PCL-5
Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36)
Time Frame: 3 months after enrollment
3 months after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

April 10, 2015

First Submitted That Met QC Criteria

April 20, 2015

First Posted (Estimate)

April 21, 2015

Study Record Updates

Last Update Posted (Estimate)

November 1, 2016

Last Update Submitted That Met QC Criteria

October 28, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 48493-G

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe